COMPASS Pathways plc (CMPS)
Nasdaq · Healthcare · Medical Care Facilities
$11.60−2.52%as of Oct 6, 2026, 4:35 AM ET
- Market cap
- $1.6B
- 52-week range
- $4.88 – $15.87
- 52-week change
- +89.19%
- EPS (trailing)
- −$3.76
- Analyst rating
- 1.3 Strong buy
- Next earnings
- Nov 3, 2026
Fiscal year to Dec 2025
- Net income
- −$270M
- Diluted EPS
- −$3.08
From the company’s annual report on SEC EDGAR.
About COMPASS Pathways plc
COMPASS Pathways plc operates as a biotechnology company that focuses on mental health in the United Kingdom and the United States. The company develops COMP360, a psilocybin therapy, which is in Phase III clinical trial for the treatment of treatment-resistant depression; and is in Phase II clinical trial for treating post-traumatic stress disorder and anorexia nervosa. The company was formerly known as COMPASS Rx Limited and changed its name to COMPASS Pathways plc in August 2020. The company was incorporated in 2020 and is headquartered in London, the United Kingdom.
Headquarters: London, United Kingdom · 156 employees · compasspathways.com